Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.45 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 4/20 | 0.43 |
| ▸ | OXER1 | Q8TDS5 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5728166 | 0.81 | MCL1 (0.50) | MCL1DAOCCR2ALDH1A1TSHR | |
| SCHEMBL8639593 | 0.78 | MCL1 (0.47) | MCL1DAOCCR2ALDH1A1TSHR | |
| SCHEMBL6682164 | 0.76 | ALDH1A1 (0.64) | MCL1DAOCCR2ALDH1A1PLA2G4A | |
| SCHEMBL9573317 | 0.76 | EPHX2 (0.47) | CCR2CNR2OXER1 | |
| SCHEMBL10762525 | 0.75 | ALDH1A1 (0.63) | MCL1DAOCCR2ALDH1A1PLA2G4A | |
| SCHEMBL8242370 | 0.75 | ALDH1A1 (0.63) | MCL1DAOCCR2ALDH1A1PLA2G4A | |
| SCHEMBL10757133 | 0.74 | ALDH1A1 (0.66) | MCL1DAOCCR2ALDH1A1TSHR | |
| SCHEMBL10379817 | 0.73 | DAO (0.59) | MCL1DAOCCR2ALDH1A1TSHR | |
| SCHEMBL9572911 | 0.73 | CNR2 (0.45) | MCL1CNR2OXER1 | |
| SCHEMBL4539369 | 0.73 | MCL1 (0.50) | MCL1DAOCCR2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332521-B2 | Substituted indoles | WYETH (US) | 2008-02-19 | — | — | US | disclosed |
| CN-1890214-A | Heterocyclic- or aryloxy, -thio or -amino substituted indoles-2-carboxylic acids or esters as pai-1 | WYETH CORP (US) | 2007-01-03 | — | — | CN | disclosed |
| EP-1667970-A1 | HETEROCYCLIC- OR ARYLOXY, -THIO 0R -AMINO SUBSTITUTED INDOLES-2-CARBOXYLIC ACIDS OR ESTERS AS PAI-1 INHIBITORS | Wyeth (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050119327-A1 | Substituted indoles | WYETH (US) | 2005-06-02 | — | — | US | disclosed |
| WO-2005030716-A1 | HETEROCYCLIC- OR ARYLOXY, -THIO OR -AMINO SUBSTITUTED INDOLES-2-CARBOXYLIC ACIDS OR ESTERS AS PAI-1 | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119327-A1 | Substituted indoles | IDO2, IDO1, TPH2 | MCL1 941/4885DAO 103/4885CCR2 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.